Bionomics Investor Presentation Deck

Emerging Leader in Neuropsychiatry Bionomics Bionomics 3 Diversified, clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious Central Nervous System (CNS) disorders H BNC210 in Phase 2 for acute treatment in Social Anxiety Disorder (SAD) – Established clinical PoC in GAD¹ and Fast Track designation from FDA for SAD BNC210 in ongoing Phase 2b ATTUNE trial with Fast Track designation from FDA for PTSD Large underserved markets with over 22 million patients in the United States alone suffering from SAD and PTSD and no new FDA approved therapies in nearly two decades Strategic partnership with Merck & Co. for cognitive impairment in Alzheimer's disease and other CNS conditions Pipeline of partnering candidates targeting potassium (Kv) and sodium (Nav) ion channels 3 Well-capitalized balance sheet with multiple potential near term value-driving milestones PoC = Proof of Concept GAD = Generalized Anxiety Disorder PTSD = Post-Traumatic Stress Disorder 1. Wise et al 2020, Biological Psychiatry; Perkins et al 2021, Molecular Psychiatry

View entire presentation